RxDoctor Payments Data

Rodney Stout, MD

Endocrinology, Diabetes & Metabolism · Gallipolis, OHNPI 1184668253

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 105 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$373
  • Novo Nordisk$180
  • Tandem Diabetes Care, Inc.$169
  • Amgen$127
  • Abbott$96
  • Insulet Corporation$80
  • plus $651 from 21 others

What the payments were for

  • Food & beverage$1,676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,676 in reported general payments places this provider in the 50th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$19,556
Medicare patients
143
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$73,066
JardianceEmpagliflozin45$56,074
MounjaroTirzepatide24$26,575
TrulicityDulaglutide16$18,710
FarxigaDapagliflozin Propanediol11$15,108
Tresiba Flextouch U-100Insulin Degludec12$9,110
ShingrixVaricella-Zoster Ge/As01b/Pf34$6,999
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$6,921
SynthroidLevothyroxine Sodium66$4,250
AbrysvoRsv Vacc, Pref A And Pref B/Pf13$3,947
Novolog FlexpenInsulin Aspart16$3,783
Levothyroxine Sodium208$2,207
Ultra-Fine Short Pen NeedlePen Needle, Diabetic13$1,604
Testosterone Cypionate30$896
Pioglitazone Hcl65$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$180$73,06635 claims
Boehringer IngelheimJardiance$45$56,07445 claims
Lilly USA, LLCMounjaro, Trulicity$68$45,28540 claims
AstraZenecaFarxiga$41$15,10811 claims
AbbVieSynthroid$15$4,25066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Gallipolis

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →